DIA Biosimilars 2013

Clinical Research Advantage

Clinical Research Advantage acquires late phase division of Comprehensive Clinical Development

Wednesday, July 24, 2013 08:29 AM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a wholly owned network of clinical trial sites, has expanded both its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD).

More... »

Cenduit: Now with Patient Reminders

Accelovance acquires CRO Radiant Development

Thursday, March 7, 2013 01:32 PM

Rockville, Md.-based CRO  Accelovance has announced the acquisition of Radiant Development, the CRO division of Radiant Research. Terms of the transaction were not disclosed. 

More... »

CRF Health – eCOA Forum

CRA receives silver Best in Biz Award for executive team of the year

Wednesday, January 2, 2013 04:01 PM

Clinical Research Advantage (CRA), a service provider based in Tempe, Ariz., received a national honor in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. CRA received the silver award for executive team of the year.

More... »

CRA, Radiant Research form largest, most therapeutically diverse SMO in U.S.

Monday, November 5, 2012 01:15 PM

CRA Holdings has acquired Radiant Research, a comprehensive research company based in Cincinnati. Clinical Research Advantage (CRA), a provider of research services also owned by CRA Holdings, will be combined with Radiant Research, creating an organization with 57 sites with more than 550 research professionals and an aggressive plan for growth.

More... »

CRA honored with 5 STEVIE Awards

Friday, June 22, 2012 02:05 PM

Tempe, Ariz.-based Clinical Research Advantage, a community-based network of clinical trial sites, was honored with three silver and two bronze STEVIE Awards at the 10th Annual American Business Awards on June 18. 

More... »

CRA wins ViE award for best clinical trial site network

Wednesday, April 18, 2012 01:02 PM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has been named best clinical trial site network bythe World Vaccine Congress.

More... »

Clinical Research Advantage adds clinical trials in rural Nebraska

Friday, March 2, 2012 01:39 PM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a provider of research services to pharmaceutical companies and CROs, will begin offering patients throughout rural Nebraska the opportunity to participate in additional clinical trials.

More... »

Clinical Research Advantage named among az magazine’s ‘Top 25 Workplaces for Women’

Friday, February 10, 2012 11:50 AM

Clinical Research Advantage (CRA), a trial management organization based in Tempe, Ariz., has been selected among az magazine’s top 25 workplaces for women.

More... »

Clinical Research Advantage Expanding to Las Vegas, Omaha

Monday, April 12, 2010 07:12 AM

After 20 years of business, site management organization (SMO) Clinical Research Advantage (CRA) is expanding beyond its home base of Phoenix buying five sites in Las Vegas and plans to open a site in Omaha, Neb.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs